Cardiovascular Medicine and Haematology articles for France

Time frame: 1 May 2025 - 30 April 2026

View topic

Count: 154

Article ‘Count’ for Cardiovascular Medicine and Haematology.

Journal Count Share
12 2.01
Idiopathic Pulmonary Fibrosis Risk Loci in East Asian Populations Mirror those of European Populations 0.03
Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension 0.08
Discriminative Performance and Clinical utility of COPD Exacerbation Categories for Predicting Future Exacerbations 0.07
International validation of electronic nose technology as diagnostic tool for fibrotic interstitial lung diseases 0.09
Effect of Dupilumab on Mucus Burden in Patients with Moderate-to-Severe Asthma: The VESTIGE Trial. 0.06
Cardiopulmonary Hemodynamic Determinants of Long-Term Survival in Sickle Cell Disease: Insights from the ETENDARD Study. 1.00
Randomized Sham Controlled Trial of Targeted Lung Denervation in Patients with COPD (AIRFLOW-3). 0.19
Inflammation and Obesity Correlate in Pulmonary Hypertension but Associate with Diverging Outcomes. 0.07
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial. 0.06
Clustering Patients with Pulmonary Hypertension Using the Plasma Proteome 0.19
Associations of Prepandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study 0.01
<atl>Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in iBMPR2/i Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)</atl> 0.16
1 0.88
A Frozen Elephant Trunk Technique to Reduce Circulatory Arrest Time in Hybrid Aortic Arch for Acute Aortic Dissection: Early and Midterm Outcomes in a Multicentric Cohort of 153 Patients. 0.88
3 1.16
Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease 0.06
Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis 0.10
Pulmonary arterial hypertension in adults with Still’s disease: another pulmonary manifestation associated with HLA-DRB1*15 1.00
4 1.30
Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database 0.12
Distinct natural killer cell signature in still's disease: Insights from a multinational immunome project consortium for autoinflammatory disorders 0.12
Drugs induced Raynaud's phenomenon and underlying mechanism: a disproportionality analysis from the WHO pharmacovigilance database 1.00
The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients with Eosinophilic Granulomatosis with Polyangiitis 0.07
3 0.56
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL 0.05
Histo–blood group ABO system transferase plasma levels and risk of future venous thromboembolism: the HUNT study 0.15
A multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypes 0.36
1 0.26
<atl>Open surgery iversus/i branched endovascular repair of the aortic arch in residual dissections after type A surgical repair</atl> 0.26
2 1.07
Incidence of new comorbidities after steroid use in patients with sarcoidosis: an international cross-sectional survey 0.07
Impact of mepolizumab on airway remodeling and inflammation in severe eosinophilic asthma 1.00
6 0.98
Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis. 0.05
CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis. 0.13
Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome 0.06
Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. 0.60
Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. 0.08
Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis 0.08
3 3.00
Preoperative and Intraoperative Risk Factors for Postoperative Pneumonia After Cardiac Surgery: An Ancillary Study of the STERNOCAT (Catheter Outcomes With Sternotomy Cardiac Operated) Randomized Trial and a Systematic Review With Meta-Analysis. 1.00
Multimodal Noninvasive Monitoring of Arterial Pressure: Do Limitations of Finger Cuff Monitoring Compromise Upper Arm Measurements? A Post Hoc Analysis of Two Prospective Cohorts. 1.00
Feasibility of High-Flow Oxygen Therapy in Apnea Testing for Brain Death Diagnosis. 1.00
1 0.92
Sympathetic innervation maintains the murine quiescent skeletal muscle stem cell pool via perivascular-derived Angpt1 0.92
1 1.00
Effects of Sodium/Glucose Cotransporter-2 Inhibitor Use on Mortality, Amputation, and Healing in Patients With Diabetic Foot Ulcer. 1.00
2 1.93
Mouldy area size and asthma symptom score and control in adults: the CONSTANCES cohort 0.93
Environmental justice in France: Analysis of the association between exposure to environmental pollution and social deprivation 1.00
1 0.08
Implications of Off-Peak Commercial Deliveries for Air Quality and Environmental Justice 0.08
21 7.67
Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry 0.09
Sex differences in cardiovascular–kidney–metabolic syndrome: the FINE-HEART pooled analysis 0.03
Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model 0.03
Laminopathies: natural history and risk prediction of heart failure 0.87
Arrhythmias in congenitally corrected transposition of the great arteries: an international study 0.30
Computed tomography-guided vs conventional catheter ablation for ventricular tachycardia: the InEurHeart trial 0.63
Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease 0.08
Pulsed field vs radiofrequency ablation for paroxysmal atrial fibrillation: the BEAT PAROX-AF trial 0.47
Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification 0.05
High-sensitivity cardiac troponin I and risk of dementia: the 25-year longitudinal Whitehall II study 0.13
Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry 0.02
Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study 1.00
Fulminant myocarditis: outcome predictors in an international cohort study 0.02
Titin-related familial dilated cardiomyopathy: factors associated with disease onset 0.07
Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction 0.39
Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis 0.11
Colchicine for secondary prevention of vascular events: a meta-analysis of trials 0.10
Immune checkpoint inhibitor-associated myocarditis: a novel risk score 0.28
Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AβYSS trial 1.00
Catheter ablation in congenital heart diseases: a French nationwide study 1.00
Cardiologist follow-up and improved outcomes of heart failure: a French nationwide cohort 1.00
1 0.11
Adherence to positive airway pressure therapy and healthcare resource utilization and costs among patients with obstructive sleep apnea and obesity 0.11
3 1.07
Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock 1.00
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria 0.04
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria 0.04
1 0.07
Wilms tumor 1 impairs apoptotic clearance of fibroblasts in distal fibrotic lung lesions 0.07
4 1.29
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 0.07
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma. 0.17
Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial. 1.00
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results. 0.05
8 3.59
Longer action potential duration in the Purkinje network than in the ventricular myocardium delays retrograde activation of the human His‐Purkinje system 0.50
A model of β‐adrenergic stimulation in human ventricular cells for tissue‐scale simulations of sympathetically modulated tachycardias 0.50
4D ultrasound reveals regional left atrial strain remodelling in a murine model of reversible pressure overload 0.50
In silico predictions of action potential propagation in doxorubicin cardiotoxicity: A parametric study using preclinical 3D magnetic resonance imaging-based fibrotic left ventricle models 0.56
Deciphering pro‐arrhythmogenic mechanisms of EPAC in human atrial cardiomyocytes 1.00
The influence of delayed ventricular activation on cardiac repolarization: Insights from electrocardiographic imaging 0.20
Computational analysis to assess hemodynamic forces in descending thoracic aortic aneurysms 0.13
The apicobasal dispersion of ventricular repolarization in humans is associated with age and affects arrhythmia vulnerability 0.20
4 2.16
Complications following airway resections: Insights from a large contemporary multi-institutional cohort 0.25
Second cross-clamp in less invasive mitral valve repair for degenerative mitral regurgitation: Predictors and outcomes 0.05
Coronary revascularization in France: six-year trends and outcomes in coronary artery bypass grafting and percutaneous coronary intervention 1.00
Mastering Aortic Valve Repair: a standardized step by step teaching approach of remodeling root replacement with external ring annuloplasty 0.86
1 0.33
Nitrite Causes Nitrosative Stress to Iron Sulfur Clusters 0.33
17 2.71
Interchangeability of the KCCQ-12 and KCCQ-23 across gt;18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure 0.08
Natriuretic Peptide Receptor-1 Agonist for Resistant Hypertension A Randomized Phase 2 Trial 0.10
Prevalence, Awareness, and Treatment of Hypertension in 37 African Countries Trends From 2003 to 2022 0.44
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multi-Domain, Patient-Level Analysis of the MAPLE-HCM Trial 0.03
One-year outcomes of novel balloon-expandable versus contemporary transcatheter heart valves in severe aortic stenosis: the LANDMARK trial 0.10
Proactive Management and Treatment of Aortic Stenosis: An International Expert Perspective 0.06
Association Between Anticoagulant Therapy and Survival in Pulmonary Arterial Hypertension A Registry Report and Updated Meta-Analysis 1.00
Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation Results in 18,000 Clinical Trial Participants 0.04
Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTOR 0.04
Effect of Aficamten Compared with Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM 0.03
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction 0.06
Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of Three Global Trials 0.04
Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction The SOGALDI-PEF Trial 0.05
3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation Results From the SWISS-APERO Randomized Clinical Trial 0.17
Differences in Arterial Events in Vascular Ehlers-Danlos, Loeys-Dietz, and Marfan Syndrome 0.25
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension Results of an International Multicenter Prospective Registry 0.17
Recurrent Events Analysis of MASTER DAPT: Total Ischemic and Bleeding Events After Abbreviated vs Prolonged DAPT in HBR Patient 0.05
2 1.02
Lymphocyte count and risk of chronic lymphocytic leukaemia 0.86
Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention 0.16
1 0.06
Clinical application of base editing for treating β-thalassaemia 0.06
13 4.57
A synthetic angiotensin II/ACE2-based hormone shunt controlling experimental hypertension 0.08
NK cells promote cardiac cell death and regulate myelopoiesis in myocardial infarction 0.67
Single-cell genomics highlight MYC-associated metabolic activation and altered cell interactions in T-prolymphocytic leukemia progression 0.16
A gut microbiome-kidney-heart axis predictive of future cardiovascular diseases 0.53
Clusters of vascular aging manifestations predict incident cardiovascular events in the community 0.53
Extracellular activation of HCN4 by a subtype-specific nanobody 0.47
Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes 0.14
Reference values for cardiac dimensions and function in a rural population living in a loiasis-endemic area of the Republic of the Congo: An echocardiographic study 0.65
Hypertrophic cardiomyopathy mutations Y115H and E497D disrupt the folded-back state of human β-cardiac myosin allosterically 0.20
Aging affects reprogramming of pulmonary capillary endothelial cells after lung injury in male mice 0.90
Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical models 0.01
Global warming may increase the burden of obstructive sleep apnea 0.20
Filamin C dimerisation is regulated by HSPB7 0.02
4 0.12
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial 0.05
Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial 0.03
Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial 0.04
Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study 0.00
1 0.90
Bone morphogenetic protein-9 controls pulmonary vascular growth and remodeling 0.90
1 0.65
Transcriptome fingerprinting of aberrant fibroblast activation unlocks effective therapeutics to tackle cardiac fibrosis 0.65
1 0.03
The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma 0.03
1 1.00
Low Emission Zone and inequalities: car restriction and reduction of air pollution exposure in the Paris region 1.00
1 0.06
Genetic characterization of preschool wheeze phenotypes 0.06
7 1.17
Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial 0.13
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial 0.07
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial 0.05
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial 0.03
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials 0.03
Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis 0.81
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial 0.04
2 0.18
Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study 0.13
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis 0.05
16 5.13
Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage 0.01
Angiography-Based Physiology to Guide Coronary Revascularization 0.08
High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure 1.00
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis 0.06
Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years 0.05
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis 0.05
Home-Based Care for Hypertension in Rural South Africa 0.08
Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction 0.70
Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation 1.00
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy 0.03
Reduction of Antihypertensive Treatment in Nursing Home Residents 0.97
Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis 0.04
Nerandomilast in Patients with Progressive Pulmonary Fibrosis 0.05
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis 0.13
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype 0.06
Identification of Hepatic-like EPO as a Cause of Polycythemia 0.84
4 1.80
Incidence and prevalence of obstructive sleep apnoea and narcolepsy in the UK: a population-based descriptive study 0.05
Elastic parametric response mapping: quantitative CT scoring for local COPD severity 0.07
Home and outpatient versus in-hospital initiation of non-invasive ventilation in people with neuromuscular and restrictive thoracic disorders: a network meta-analysis 1.00
Impact of long-term non-invasive ventilation on severe exacerbations and survival in COPD: a French nationwide cohort study using multistate models 0.69

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.